Reversing agent for drug-fast during treating tumor with multiple medicines
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- 广州中医药大学热带医学研究所
- Publication Date
- 2007-02-14
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to a new tumor cell multidrug resistance reversing agent capable of producing medicine. Specifically, it relates to a derivative of Tenacigenin B (also known as Tongguang Scattering Aglycone B, or Tongguang Scattering Aglycone B, English name Tenacigenin B), and dihydroscarptinin ( Also known as Dihydrosarcosarginin, English name Dihydrosarcostin) derivatives and Tongguang scatter aglycon C (also known as Tongguang scatter aglycon C, or Tongguang scatter aglycon C, English name Tenacigenin C) derivatives The application of natural or semi-synthetic derivatives of steroid structure in the preparation of tumor cell multidrug resistance reversal agents. Background technique
[0002] Multidrug resistance (MDR) of tumor cells means that after tumor cells develop resistance to one anticancer drug, they can simultaneously develop cross-resistance to other anticancer drugs that have not been exposed to each other with different chemical ...